- Home
- NRIX vs HSTM Comparison
NRIX vs HSTM Comparison
Compare NRIX & HSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- HSTM
- Stock Information
- Founded
- NRIX 2009
- HSTM 1990
- Country
- NRIX United States
- HSTM United States
- Employees
- NRIX N/A
- HSTM N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- HSTM Computer Software: Programming Data Processing
- Sector
- NRIX Health Care
- HSTM Technology
- Exchange
- NRIX Nasdaq
- HSTM Nasdaq
- Market Cap
- NRIX 952.9M
- HSTM 851.7M
- IPO Year
- NRIX 2020
- HSTM 2000
- Fundamental
- Price
- NRIX $11.49
- HSTM $26.60
- Analyst Decision
- NRIX Strong Buy
- HSTM Hold
- Analyst Count
- NRIX 16
- HSTM 2
- Target Price
- NRIX $30.44
- HSTM $29.00
- AVG Volume (30 Days)
- NRIX 796.7K
- HSTM 212.6K
- Earning Date
- NRIX 07-10-2025
- HSTM 07-21-2025
- Dividend Yield
- NRIX N/A
- HSTM 0.47%
- EPS Growth
- NRIX N/A
- HSTM 8.37
- EPS
- NRIX N/A
- HSTM 0.63
- Revenue
- NRIX $56,417,000.00
- HSTM $292,371,000.00
- Revenue This Year
- NRIX $16.69
- HSTM $5.00
- Revenue Next Year
- NRIX N/A
- HSTM $5.20
- P/E Ratio
- NRIX N/A
- HSTM $43.64
- Revenue Growth
- NRIX N/A
- HSTM 3.36
- 52 Week Low
- NRIX $8.18
- HSTM $25.72
- 52 Week High
- NRIX $29.56
- HSTM $34.24
- Technical
- Relative Strength Index (RSI)
- NRIX 50.78
- HSTM 33.10
- Support Level
- NRIX $12.25
- HSTM $27.16
- Resistance Level
- NRIX $12.00
- HSTM $28.65
- Average True Range (ATR)
- NRIX 0.69
- HSTM 0.59
- MACD
- NRIX -0.08
- HSTM -0.02
- Stochastic Oscillator
- NRIX 21.57
- HSTM 26.13
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About HSTM HealthStream Inc.
HealthStream Inc provides workforce and provider solutions for healthcare organizations. Its reportable segments include Workforce Solutions and Provider Solutions. Workforce development solutions consist of SaaS, subscription-based products that are used by healthcare organizations. Its Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment activities. The company generates a majority of its revenue from Subscription Services.